Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1169852 | 0.88 | TSHR (0.60) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL3292782 | 0.86 | TSHR (0.75) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL1312325 | 0.86 | TSHR (0.58) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL4768686 | 0.85 | TSHR (0.49) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL7943874 | 0.84 | KCNH2 (0.59) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL439 | 0.82 | LOXL2 (0.61) | TSHRLOXL2KCNH2KCNJ1IDO1 | |
| SCHEMBL18913824 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL30758863 | 0.82 | TSHR (0.69) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL8094543 | 0.80 | POLB (0.68) | TSHRLOXL2KCNH2KCNJ1HRH3 | |
| SCHEMBL2588477 | 0.80 | TSHR (0.67) | TSHRLOXL2KCNH2KCNJ1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791389-A | Preparation method of mirabegron intermediate | 山东四环药业股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-111647001-B | Fluorescent probe based on small molecule inhibitor and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2021-11-12 | — | — | CN | claimed |
| CN-112876474-A | Dimethoxy tetrahydroisoquinoline substituted purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-01 | — | — | CN | claimed |
| CN-112724124-A | 4-hydroxyquinoline derivatives, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-04-30 | — | — | CN | claimed |
| US-5064956-A | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1991-11-12 | — | — | US | claimed |
| WO-1990007261-A2 | PROCESS FOR PREPARING MONO-N-ALKYLATED POLYAZAMACROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | claimed |
| EP-0374929-A1 | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1990-06-27 | — | — | EP | claimed |
| EP-0239354-A2 | 2,2-Dinitrophenylethane derivatives and their application as protecting compounds | Wendstone Chemicals P.L.C. (GB) | 1987-09-30 | — | — | EP | claimed |
| CN-121779682-A | Liquid modified dicyandiamide curing agent, preparation method and application | 安庆天赢新材料科技有限公司 | 2026-04-03 | — | — | CN | disclosed |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORP (US) | 2026-01-15 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-119707835-A | 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-0089743-A1 | Novel 2,5-benzodiazocines and salts thereof having pharmaceutical activity | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1983-09-28 | — | — | EP | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4097669-A | FUNGICIDES, BACTERICIDES, INSECTICIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-06-27 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
| US-3937708-A | CNS-DEPRESSANTS, NEUROLEPTICS, ANALGESICS, ANTIPHLOGISTICS, SPASMOLYTICS, BRONCHOLYTICS, HYPOTENSIVES, ANTICHOLESTEREMICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-02-10 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | TSHR 3859/4885LOXL2 2320/4885KCNH2 4429/4885 |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | MDM2, TP53, VHL | TSHR 3247/4885LOXL2 1264/4885KCNH2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.